Avanos Medical FY2025 EPS Estimate Cut by Zacks Research

Avanos Medical, Inc. (NYSE:AVNS) – Zacks Research cut their FY2025 EPS estimates for shares of Avanos Medical in a report released on Wednesday, November 26th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.89 for the year, down from their previous forecast of $0.92. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q4 2025 earnings at $0.24 EPS, Q1 2026 earnings at $0.23 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.27 EPS, Q4 2026 earnings at $0.36 EPS, FY2026 earnings at $1.08 EPS, Q1 2027 earnings at $0.33 EPS, Q2 2027 earnings at $0.32 EPS, Q3 2027 earnings at $0.26 EPS and FY2027 earnings at $1.24 EPS.

Several other analysts have also recently commented on the stock. Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Avanos Medical in a report on Tuesday, November 25th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Avanos Medical Price Performance

Shares of AVNS stock opened at $11.74 on Monday. The stock’s fifty day moving average is $11.48 and its 200-day moving average is $11.80. The stock has a market capitalization of $544.97 million, a PE ratio of -1.15 and a beta of 1.09. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.36 and a current ratio of 2.38. Avanos Medical has a 52 week low of $9.30 and a 52 week high of $19.91.

Avanos Medical (NYSE:AVNS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.10. The firm had revenue of $177.80 million for the quarter, compared to analysts’ expectations of $164.50 million. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.33 earnings per share. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS.

Insider Buying and Selling

In other Avanos Medical news, SVP Kerr Holbrook sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $11.00, for a total transaction of $165,000.00. Following the completion of the sale, the senior vice president owned 83,860 shares in the company, valued at approximately $922,460. The trade was a 15.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.64% of the company’s stock.

Institutional Investors Weigh In On Avanos Medical

A number of institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc increased its holdings in Avanos Medical by 49.7% in the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock valued at $31,000 after purchasing an additional 894 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Avanos Medical by 969.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after buying an additional 2,307 shares during the period. Wexford Capital LP bought a new stake in shares of Avanos Medical in the 3rd quarter valued at about $70,000. Tower Research Capital LLC TRC increased its stake in shares of Avanos Medical by 433.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock valued at $77,000 after acquiring an additional 5,083 shares during the last quarter. Finally, Quantessence Capital LLC acquired a new stake in shares of Avanos Medical in the 3rd quarter valued at approximately $116,000. 95.17% of the stock is owned by institutional investors and hedge funds.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.